

# SCIENTIFIC REPORTS



OPEN

## Sedation of mechanically ventilated adults in intensive care unit: a network meta-analysis

Zhongheng Zhang<sup>1</sup>, Kun Chen<sup>2</sup>, Hongying Ni<sup>2</sup>, Xiaoling Zhang<sup>2</sup> & Haozhe Fan<sup>2</sup>

Received: 29 July 2016

Accepted: 20 February 2017

Published: 21 March 2017

Sedatives are commonly used for mechanically ventilated patients in intensive care units (ICU). However, a variety of sedatives are available and their efficacy and safety have been compared in numerous trials with inconsistent results. To resolve uncertainties regarding usefulness of these sedatives, we performed a systematic review and network meta-analysis. Randomized controlled trials comparing sedatives in mechanically ventilated ICU patients were included. Graph-theoretical methods were employed for network meta-analysis. A total of 51 citations comprising 52 RCTs were included in our analysis. Dexmedetomidine showed shorter MV duration than lorazepam (mean difference (MD): 68.7; 95% CI: 18.2–119.3 hours), midazolam (MD: 10.2; 95% CI: 7.7–12.7 hours) and propofol (MD: 3.4; 95% CI: 0.9–5.9 hours). Compared with dexmedetomidine, midazolam was associated with significantly increased risk of delirium (OR: 2.47; 95% CI: 1.17–5.19). Our study shows that dexmedetomidine has potential benefits in reducing duration of MV and lowering the risk of delirium.

The management of critically ill patients often requires invasive and uncomfortable procedures such as tracheal intubation and physical restraint. Furthermore, the intensive care unit (ICU) environment is filled with noise, which greatly exaggerates the stress and anxiety of conscious patients<sup>1</sup>. There is evidence that stress and anxiety have adverse effects on clinical outcomes, and prevention of exposure to environmental noise can help to improve outcome<sup>2,3</sup>. An alternative but important modality is the use of sedatives to prevent critically ill patients from being exposed to hazardous physical and psychological stimulus<sup>4</sup>.

Mechanical ventilation (MV) is among the most commonly used techniques in the ICU. Because of its invasiveness, MV usually brings stressful, uncomfortable and even painful experience to ICU patients<sup>5,6</sup>. MV patients are at increased risk of developing delirium<sup>7</sup>. Therefore, international guideline recommends routine use of sedation to fully prevent patients from exposure to these adverse stimuli. However, there is a variety of sedatives that are available for clinical use, including midazolam, dexmedetomidine, propofol and lorazepam<sup>8</sup>. They have different advantages and limitations in clinical use, due to their distinct pharmacological properties. In clinical practice, clinicians usually face with the choice between multiple alternative sedatives. The choice may become difficult when investigators have undertaken head-to-head comparisons of only some of available sedatives. Network meta-analysis allows for simultaneous comparisons of multiple sedatives against each other, providing direct evidence on the choice among multiple sedatives. In this study we performed a systematic review and network meta-analysis of the efficacy and safety of these sedatives, in the hope that it will provide updated and unbiased evidence for clinical practice.

### Methods

**Study population and registration.** The study population was critically ill adult patients who required MV. Critically ill patients were defined as those treated in the ICU and were defined as per the original studies. MV included both invasive and non-invasive modes. Pediatric patients (younger than 12 years old) were excluded. Patients included medical patients requiring long-term MV and patients underwent major operation that were transferred to ICU. The study was registered at PROSPERO (CRD42016041920).

**Interventions.** Sedatives of any types were deemed suitable for inclusion. However, studies investigating sedation protocol but the types of sedatives are not distinguishable were excluded. Sedatives included midazolam,

<sup>1</sup>Department of emergency medicine, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China. <sup>2</sup>Department of critical care medicine, Jinhua municipal central hospital, Jinhua hospital of Zhejiang university, Zhejiang, P. R. China. Correspondence and requests for materials should be addressed to Z.Z. (email: zh\_zhang1984@hotmail.com)

dexmedetomidine, propofol, clonidine and lorazepam. Studies with one arm involving these sedatives were included. The other arms can be atypical sedatives such as haloperidol, morphine and combination of two types of sedatives. Dexmedetomidine was employed as the base comparator, and other sedatives were compared to it.

**Outcomes.** The primary outcome was the duration of MV. Other outcomes included Richmond Agitation Sedation Scale (RASS), Ramsay Sedation Scale (RSS), ICU and hospital length of stay (LOS).

**Search strategy and data extraction.** Electronic databases including Pubmed, SCOPUS, ISI web of science, and EMBASE were searched from inception to April 2016. There was no language restriction. Search items included core terms related to critical care, mechanical ventilation, outcomes and sedatives. Examples of searching strategy in PubMed and SCOPUS, as well as the number of extracted citations were provided in supplemental file. Reference lists of relevant articles were screened by hand for potential eligible studies.

Custom-made form was employed to extract data from included trials. Characteristics of studies included the name of the first author, publication year, type of study population, sample size, comparator in each arm and study outcomes. Numerical data on the number of participants in each arm, names of comparators, number of events in each arm, and mean (standard error) were extracted. Two authors (X.Z. and H.F.) independently extracted data, and disagreement was settled by a third opinion (Z.Z.). If the original article reported median and interquartile range, its distribution was assumed to be normal. Data on mean and standard error can be derived according to normal distribution rules. Some continuous outcomes were reported in median and range. They were converted to mean (standard error) according to the equations proposed by Hozy and coauthors<sup>9</sup>.

**Quality assessment of component trials.** Only randomized controlled trials were included in our study. Therefore, the qualities of trials were assessed in six aspects: (1) random sequence generation, (2) allocation concealment, (3) blinding of participants and personnel, (4) blinding of outcome assessor (5) incomplete data outcome, (6) selective reporting, and (7) other bias. These items were adapted from the Cochrane Collaboration's tool for assessing risk of bias<sup>10</sup>.

**Statistical analysis.** There were two types of outcome data: continuous and binary outcomes. The former included ICU and hospital LOS, and duration of MV. RASS and RSS were ordinal variables. Binary outcomes included mortality, atrial fibrillation and delirium. Mean difference (MD) was reported for the comparison of continuous outcomes between interventions, and odds ratio (OR) was reported for binary outcomes.


Graph-theoretical methods, which have been routinely applied to electrical networks, were employed for network meta-analysis<sup>11</sup>. Direct comparisons between sedatives were derived from each of the two-arm trials, and were represented by edges in a network plot. Effect sizes from component trials were weighted by the inverse of the observed variance of the treatment effect. For a meta-analytic network, the node corresponds to a treatment strategy, and the edge represents the existing comparisons between treatments. Each two-arm study (e.g. randomized controlled trial) contributes to one comparison. The thickness of the edge is proportional to inverse standard error of random effects model comparing two treatments. Additionally, we employed net heat plot to highlight hot spots of inconsistency between specific direct and indirect evidence in the whole network<sup>12</sup>. The area of a gray square displays the contribution of the direct estimate of one design in the column to a network estimate in a row. The colors are associated with the change in inconsistency between direct and indirect evidence in row design after detaching the effect of column design. Forest plots were employed to show the effect size of each drug, by setting dexmedetomidine as the reference. Effect sizes and corresponding 95% confidence intervals were reported in the forest plots. All statistical analyses were performed using R (version 3.2.3)<sup>13</sup>.

## Results

**Included studies and characteristics.** The initial search identified 598 citations. Another 9 studies were added from the references of relevant articles (Fig. 1). After removing duplicates, a total of 203 citations remained for further screening. The titles and abstracts were screened by hand and 125 were excluded because 18 were related to anesthesia, one was animal study, 57 were irrelevant studies, 12 were observational studies, 11 involved pediatric patients, and 26 were reviews. The full-text articles of the remaining 78 citations were screened. Twenty-seven articles were excluded because 20 investigated sedation protocol that the type of sedative drugs could not be identified, 4 studies were secondary analysis of previous reports, and 3 were study protocols. As a result, a total of 51 citations comprising 52 RCTs were included in our analysis<sup>14–64</sup>. The article by Jakob and colleagues comprised two RCTs<sup>38</sup>. Characteristics of component trials are shown in Table 1. These articles were published between the year 1989 and 2016. Study populations included patients underwent major operations requiring ICU admission, and those requiring long-term MV. The sample sizes in included trials ranged from 20 to 500. Most of the trials were two-arm trials, and there were five three-arm trials<sup>20,35,42,63,64</sup>. Study endpoints included duration of MV, Richmond Agitation Sedation Scale (RASS), Ramsay Sedation Scale (RSS), ICU and hospital length of stay (LOS). Adverse events included bradycardia, hypotension and death.

**Risk of bias.** Random sequence generation was adequately described in approximately half of included trials (Fig. 2). In the remaining trials, they did not specifically describe the method of sequence generation. Allocation concealment was properly done in about 21 of the 52 trials. Blinding was difficult to perform because propofol was distinctive in appearance. Attrition bias and reporting bias were generally well performed in included trials. Risk of bias assessment of each trial is present in Supplemental Fig. 1.

Network graph for the duration of MV is shown in Fig. 3. Collectively, there were 8 sedatives being compared. They were midazolam, dexmedetomidine, propofol, clonidine, morphine, haloperidol, clonidine and lorazepam. The placebo meant that no sedative was given in that group. Two studies employed propofol and midazolam in combination as the control arm, and we denoted it as the standard<sup>20,53</sup>. The thickness of the edge is proportional



**Figure 1.** PRISMA flow diagram for study inclusion.

to inverse standard error of random effects model comparing two treatments. For example, the dex-propofol comparison appears to be thick, indicating a small standard error for the effect size of the comparison (Fig. 3). Multi-arm studies were highlighted with blue color.

**Clinical outcomes.** MV duration was reported in most studies. Random effects model was employed to combine the results. Dexmedetomidine showed shorter MV duration than lorazepam (MD: 68.74; 95% CI: 18.2–119.3 hours), midazolam (MD: 10.2; 95% CI: 7.7–12.7 hours) and propofol (MD: 3.4; 95% CI: 0.9–5.9 hours). However, MV duration in dexmedetomidine group was longer than clonidine (MD: –9.4; 95% CI: –16.1––2.7 hours) and placebo (MD: –5.2 95% CI: –11.4–0.99 hours). There were no significant differences for MV duration in dexmedetomidine group as compared to that in haloperidol, morphine, sevoflurane and standard groups (Fig. 4). There were large changes in inconsistency between direct and indirect evidence in design dex:pro (shown in the row) after detaching the effect of corresponding column design (Fig. 5). As compared to dexmedetomidine, midazolam was associated with significantly increased risk of delirium (OR: 2.47; 95% CI: 1.17–5.19). Propofol was associated with increased risk of delirium with marginal statistical significance (OR: 2.14; 95% CI: 0.94–4.89). There was no difference in the risk of delirium in other comparisons (Fig. 6). There was no difference in the ICU LOS in all comparisons (Suppl. Fig. 2), except that haloperidol was associated with longer ICU stay (MD: 5; 95% CI: 1.8–8.2 days). Dexmedetomidine was associated with shorter LOS in hospital than propofol (MD: 4.6; 95% CI: 1.2–8.1 days, Suppl. Fig. 3). There is no difference in mortality between dexmedetomidine and other sedatives (Suppl. Fig. 4). There were no differences in RSS, RASS or atrial fibrillation between dexmedetomidine and other comparators (Suppl. Figs 5 to 7).

## Discussion


The present study showed that dexmedetomidine was able to reduce MV duration in critically ill patients, as compared to conventional sedatives such as lorazepam, midazolam and propofol. In addition, dexmedetomidine was associated with lower risk of delirium than that of midazolam and propofol. Dexmedetomidine was also associated with shorter hospital LOS than propofol. Propofol showed a shorter MV duration when compared to midazolam, and it has similar risk of delirium to midazolam. There were no significant differences between sedatives in other important outcomes such as mortality, ICU and hospital LOS.

Several meta-analyses of sedatives in critically ill patients have been conducted before our study<sup>65–67</sup>. Fraser's study included only 6 trials comparing Benzodiazepine versus nonbenzodiazepine-based sedation for the mechanically ventilated patients. Numerous studies in this area have been published since that time, and the evidence needs to be updated. In our study, we included 51 citations that were far more than that included in


Studies	Study population or setting	Sample size	Comparators	Outcomes
Abd Aziz <sup>14</sup>	Cardiac surgery	28	DEX; morphine	Sedation scores; pain; HR; ABP; extubation time
Aghdai <sup>15</sup>	CABG	50	Propofol; Midazolam	BP; HR; extubation time; ICU LOS
Aitkenhead <sup>16</sup>	MV > 12 H	101	Propofol; Midazolam	MV duration; BP; HR; biochemistry profile
Aydogan <sup>17</sup>	Scoliosis surgery	32	DEX; Midazolam	Adverse events; MV duration; ICU LOS
Balkanay <sup>18</sup>	CABG	90	Placebo; DEX	Renal injury; hospital and ICU stay
Barrientos-Vega <sup>19</sup>	MV > 24 h	108	Propofol; Midazolam	Cost; extubation time; mortality;
Carrasco <sup>20</sup>	CABG	75	Propofol; Midazolam; Propofol + Midazolam	HR; BP; extubation time
Carson <sup>21</sup>	Medical ICU; MV > 48 hours	132	Lorazepam; propofol	Ventilator days; 28-day ventilator-free survival, ICU and hospital LOS, and hospital mortality.
Cernaianu <sup>22</sup>	MV	95	Lorazepam; Midazolam	HR; MAP; hemodynamic parameters;
Chamorro <sup>23</sup>	MV > 48 h	98	Propofol; Midazolam	Sedation efficacy; hypotension;
Corbett <sup>24</sup>	CABG	89	DEX; propofol	Perception of ICU experience
Djaiani <sup>25</sup>	Cardiac surgery	183	DEX; propofol	Delirium; extubation time;
Abdulatif <sup>26</sup>	MV	40	DEX; propofol	
Elbaradie <sup>27</sup>	Postoperative MV	60	DEX; propofol	RSS; BIS; extubation time
Eremenko <sup>28</sup>	Cardiac surgery	55	DEX; propofol	Duration of MV; adverse events;
Esmoğlu <sup>29</sup>	Eclampsia	40	Midazolam; DEX	Heart rate, blood pressure, RSS; ICU LOS;
Gupta <sup>30</sup>	Postabdominal surgery MV > 24 h	40	Midazolam; DEX	Heart rate; ICU LOS; duration of MV
Hall <sup>31</sup>	MV	99	Midazolam; propofol	ICU LOS; duration of MV
Hellström <sup>32</sup>	Cardiac surgery	99	Sevoflurane; propofol	ICU and hospital LOS; duration of MV; agitation
Herr <sup>33</sup>	CABG	295	DEX; propofol	Adverse events; extubation time
Higgins <sup>34</sup>	CABG	84	Propofol; midazolam	HR; BP; cardiac output
Hu <sup>35</sup>	ICU MV > 24 h	76	DEX; propofol; midazolam	extubation time; delirium; adverse events;
Huang <sup>36</sup>	Non-invasive MV	62	DEX; midazolam	Delirium; ICU LOS; duration of MV; adverse events
Huang <sup>37</sup>	Major surgery MV	108	DEX; propofol	Adverse events; ICU LOS; duration of MV
Jakob <sup>38</sup>	Prolonged MV	500 + 498	DEX; propofol; midazolam	ICU LOS; RASS; duration of MV
Jalonen <sup>39</sup>	CABG	80	DEX; placebo	Hemodynamics; myocardial function;
Kim <sup>40</sup>	CABG	153	DEX; placebo	ICU and hospital LOS; mortality; cardiac function
MacLaren <sup>41</sup>	Mixed ICU; MV > 12 h	23	DEX; midazolam	Duration of MV; ICU LOS
Maldonado <sup>42</sup>	Cardiac surgery	90	DEX; midazolam; propofol	Duration of MV; ICU and hospital LOS
Memis <sup>43</sup>	Septic shock	40	DEX; propofol	Hemodynamics, ICU LOS; mortality
Pandharipande <sup>44</sup>	Mixed ICU; MV > 120 h	103	DEX; lorazepam	Duration of MV; ICU LOS; mortality; efficacy of sedation
Reade <sup>45</sup>	Delirious MV	20	Haloperidol; DEX	MV duration; adjunct propofol; ICU LOS
Reade <sup>46</sup>	Agitated delirium	71	DEX; placebo	duration of MV; ICU and hospital LOS; mortality
Ren <sup>47</sup>	CABG	162	DEX; placebo	BP; HR; other arrhythmia
Riker <sup>48</sup>	MV > 3 d	366	DEX; midazolam;	duration of MV; ICU LOS; mortality; delirium
Roekaerts <sup>49</sup>	Coronary artery surgery	30	Midazolam; propofol	BP; HR; extubation time;
Rubino <sup>50</sup>	Surgery for type-A aortic dissection	30	Clonidine; placebo	Delirium; duration of MV; ICU LOS;
Ruokonen <sup>64</sup>	MV requiring long-term sedation	85	DEX; midazolam; propofol	duration of MV; ICU LOS; delirium
Sakarya <sup>51</sup>	CABG	40	midazolam; propofol	Adverse events; MV duration
Shah <sup>52</sup>	Postoperative MV	30	DEX; propofol	Safety and efficacy;
Shehabi <sup>53</sup>	MV > 12 h	37	DEX-based EGDS; standard care	ICU and hospital LOS; mortality; delirium; MV duration
Continued				

Studies	Study population or setting	Sample size	Comparators	Outcomes
Shehabi <sup>54</sup>	Cardiac surgery	299	DEX; morphine	Delirium; ICU and hospital LOS; mortality; adverse events
Song <sup>55</sup>	ICU MV > 3d	90	DEX; midazolam	Delirium; ICU LOS;
Soro <sup>56</sup>	CABG	73	Sevoflurane; propofol	ICU and hospital LOS; mortality; adverse events
Srivastava <sup>57</sup>	MV > 12 h	70	Clonidine; DEX	MV duration; hypotension; bradycardia
Tasdogan <sup>58</sup>	Severe sepsis	40	DEX; propofol	Mortality; IAP; MV duration; ICU LOS
Venn <sup>59</sup>	Postoperative MV > 8 h	20	DEX; propofol	RSS; BIS; MV duration; ICU LOS
Wan <sup>60</sup>	SICU	200	DEX; midazolam	Delirium; MV duration; ICU LOS
Weinbroum <sup>61</sup>	MV	67	Midazolam; propofol	Hypotension; agitation;
Yapici <sup>62</sup>	Cardiac surgery	72	DEX; midazolam	MV duration; RASS;
Zhang <sup>63</sup>	COPD MV > 48 h	162	Midazolam; propofol; control	Vital signs; extubation time;


**Table 1. Characteristics of included studies.** CABG: coronary artery bypass grafting; DEX: Dexmedetomidine; MV; mechanical ventilation; RSS: Ramsay sedation score; BIS: bispectral index; ICU: intensive care unit; LOS: length of stay; EGDS: early-goal directed sedation; IAP: intra-abdominal pressure; SICU: surgical ICU.




**Figure 2. Summary of risk of bias for included trials.**



**Figure 3. Network of comparators.** The nodes in the graph correspond to sedatives and edges display the observed treatment comparisons. The thickness of the edge is proportional to inverse standard error of random effects model comparing two treatments. For example, the dex-propofol comparison appears to be thick, indicating a small standard error for the effect size. Multi-arm studies were highlighted with blue color. For example, there is a study with three arms comprising midazolam, propofol and placebo. The triangle involving these three alternative treatments is filled with blue color.




**Figure 4. Difference in duration of mechanical ventilation between comparators.** Dexmedetomidine was used as the reference.



**Figure 5. Net heat plot highlights the inconsistency between specific direct and indirect evidence in the whole network.** The effect estimates in the row represents pooled effect of direct and indirect effects, and the effects in the column corresponds to the direct effect. There are gray squares in some cells, and the area size is proportional to the contribution of one design in a column that is estimated from direct comparison to an overall network estimate in a row. Also note there are different colors in the cells. After detaching the effect of column design, there will be a change in the inconsistency between direct and indirect estimates. Blue colors indicate an increase in the inconsistency between direct and indirect estimates, and warm colors indicate the opposite (the intensity of the color is proportional to the magnitude of change). The pairwise contrasts corresponding to designs of three-arm studies are marked by the symbol ‘\_’ following the treatments of the design.

Fraser’s study. Furthermore, previous studies did not perform meta-analysis in network framework. By using conventional pairwise meta-analysis, many types of sedatives had to be combined as the control group, ignoring the fact that these sedatives were different in their pharmacological properties. In clinical practice, clinicians usually face with the choice between multiple alternative sedatives. The choice may become difficult when investigators



**Figure 6.** Odds of delirium in each sedative, as compared to that in dexmedetomidine group.

have undertaken head-to-head comparisons of only some of available sedatives. Chen's study highlighted dexmedetomidine, and other sedatives were used as the controls. Cruickshank's study also had the same limitation. We believe that all other sedatives are different in their efficacy and safety profiles. In this situation, network meta-analysis is more appropriate because it allows for simultaneous comparisons of multiple interventions against each other. With respect to searching database, SCOPUS was not searched in Cruickshank's study. In the present study, many publications in non-English language were retrieved from SCOPUS. Missing these citations may result in biased estimates of pooled results, also known as publication bias. Although there are significant differences in included trials, some aspects of our findings are consistent with previous meta-analyses. For example, Cruickshank's study found that dexmedetomidine was effective in reducing time to extubation in the ICU patients, and risk of bradycardia but not of overall mortality is higher among patients treated with dexmedetomidine<sup>67</sup>. However, Fraser's study found a similar prevalence of delirium between patients treated with benzodiazepine versus nonbenzodiazepine sedatives<sup>65</sup>. This discrepancy can be partly explained by the limited number of component trials and the combination of different types of sedatives as the control group.

Several limitations in our study need to be acknowledged. First, the study population involved critically ill patients that were heterogeneous in nature. Patients after major operation and medical ICU patients requiring long-term MV were enrolled. However, the common feature was that they all needed MV, and sedatives were used for the same purpose for them. Second, there were significant risks of bias in most of enrolled trials. For example, blinding to participants and investigators was not performed due to the appearance of propofol. Also, specific methods to generate random sequence were not explicitly reported in nearly half of the trials. Third, more than two thirds of component trials had a sample size of less than 100, which were typically small studies. As a result, the systematic review may be subject to small study effect bias<sup>68</sup>.

In conclusion, our study showed that dexmedetomidine had potential benefits in reducing duration of MV and lowering the risk of delirium. Propofol is considered superior to midazolam in terms of MV duration. Adverse events of hypotension and bradycardia should be closely monitored when sedatives are used for MV patients.

## References

- Czaplik, M. *et al.* Psychoacoustic analysis of noise and the application of earplugs in an ICU: A randomised controlled clinical trial. *Eur J Anaesthesiol* **33**, 14–21 (2016).
- Van Rompaey, B., Elseviers, M. M., Van Drom, W., Fromont, V. & Jorens, P. G. The effect of earplugs during the night on the onset of delirium and sleep perception: a randomized controlled trial in intensive care patients. *Crit Care* **16**, R73 (2012).
- Hu, R.-F., Jiang, X.-Y., Hegadoren, K. M. & Zhang, Y.-H. Effects of earplugs and eye masks combined with relaxing music on sleep, melatonin and cortisol levels in ICU patients: a randomized controlled trial. *Crit Care* **19**, 115 (2015).
- Sneyers, B., Laterre, P.-F., Perreault, M. M., Wouters, D. & Spinewine, A. Current practices and barriers impairing physicians' and nurses' adherence to analgo-sedation recommendations in the intensive care unit—a national survey. *Crit Care* **18**, 655 (2014).
- Prime, D. *et al.* Patient experiences during awake mechanical ventilation. *J Community Hosp Intern Med Perspect* **6**, 30426 (2016).
- Fink, R. M., Makic, M. B. F., Poteet, A. W. & Oman, K. S. The Ventilated Patient's Experience. *Dimens Crit Care Nurs* **34**, 301–308 (2015).
- Mehta, S. *et al.* Prevalence, risk factors, and outcomes of delirium in mechanically ventilated adults. *Critical Care Medicine* **43**, 557–566 (2015).
- Shehabi, Y., Bellomo, R., Mehta, S., Riker, R. & Takala, J. Intensive care sedation: the past, present and the future. *Crit Care* **17**, 322 (2013).
- Hozo, S. P., Djulbegovic, B. & Hozo, I. Estimating the mean and variance from the median, range, and the size of a sample. *BMC Med Res Methodol* **5**, 13 (2005).
- Cochrane Handbook for Systematic Reviews of Interventions*. 1–649 (John Wiley & Sons, Ltd, doi: 10.1002/9780470712184 (2008).
- Rücker, G. Network meta-analysis, electrical networks and graph theory. *Res Synth Methods* **3**, 312–324 (2012).
- Krahn, U., Binder, H. & König, J. A graphical tool for locating inconsistency in network meta-analyses. *BMC Med Res Methodol* **13**, 35 (2013).

13. Neupane, B., Richer, D., Bonner, A. J., Kibret, T. & Beyene, J. Network Meta-Analysis Using R: A Review of Currently Available Automated Packages. *PLoS ONE* **9**, e115065 (2014).
14. Abd Aziz, N. *et al.* Efficacy and safety of dexmedetomidine versus morphine in post-operative cardiac surgery patients. *Int J Clin Pharm* **33**, 150–154 (2011).
15. Aghdaii, N., Yazdani, F. & Faritus, S. Z. Sedative Efficacy of Propofol in Patients Intubated/Ventilated after Coronary Artery Bypass Graft Surgery. *Anesth Pain Med* **3** (2014).
16. Aitkenhead, A. R. *et al.* Comparison of propofol and midazolam for sedation in critically ill patients. *Lancet* **2**, 704–709 (1989).
17. Aydogan, M. S. *et al.* Pain, fentanyl consumption, and delirium in adolescents after scoliosis surgery: dexmedetomidine vs midazolam. *Paediatr Anaesth* **23**, 446–452 (2013).
18. Balkanay, O. O., Goksef, D., Omeroglu, S. N. & Ipek, G. The dose-related effects of Dexmedetomidine on renal functions and serum neutrophil gelatinase-associated lipocalin values after coronary artery bypass grafting: a randomized, triple-blind, placebo-controlled study. *Interactive Cardiovascular and Thoracic Surgery* **20**, 209–214 (2015).
19. Barrientos-Vega, R. *et al.* Prolonged sedation of critically ill patients with midazolam or propofol: impact on weaning and costs. *Critical Care Medicine* **25**, 33–40 (1997).
20. Carrasco, G. *et al.* Synergistic sedation with propofol and midazolam in intensive care patients after coronary artery bypass grafting. *Critical Care Medicine* **26**, 844–851 (1998).
21. Carson, S. S. *et al.* A randomized trial of intermittent lorazepam versus propofol with daily interruption in mechanically ventilated patients\*. *Critical Care Medicine* **34**, 1326–1332 (2006).
22. Cernaianu, A. C. *et al.* Lorazepam and midazolam in the intensive care unit: a randomized, prospective, multicenter study of hemodynamics, oxygen transport, efficacy, and cost. *Critical Care Medicine* **24**, 222–228 (1996).
23. Chamorro, C. *et al.* Comparative study of propofol versus midazolam in the sedation of critically ill patients: results of a prospective, randomized, multicenter trial. *Critical Care Medicine* **24**, 932–939 (1996).
24. Corbett, S. M. *et al.* Dexmedetomidine does not improve patient satisfaction when compared with propofol during mechanical ventilation. *Critical Care Medicine* **33**, 940–945 (2005).
25. Djajani, G. *et al.* Dexmedetomidine versus Propofol Sedation Reduces Delirium after Cardiac Surgery: A Randomized Controlled Trial. *Anesthesiology* **124**, 362–368 (2016).
26. Abdulatif, M. A comparative study of the use of dexmedetomidine and propofol as sedatives for mechanically ventilated patients in ICU. *Egyptian Journal of Anaesthesia* **20**, 437–442 (2004).
27. Elbaradie, S., Mahalawy, El, F. H. & Solyman, A. H. Dexmedetomidine vs. propofol for short-term sedation of postoperative mechanically ventilated patients. *J Egypt Natl Canc Inst* **16**, 153–158 (2004).
28. Eremenko, A. [Comparison of dexmedetomidine and propofol for short-term sedation in early postoperative period after cardiac surgery]. *Anesteziologija i reanimatologija* 37–41 (2014).
29. Esmaoglu, A., Ulgey, A., Akin, A. & Boyaci, A. Comparison between dexmedetomidine and midazolam for sedation of eclampsia patients in the intensive care unit. *Journal of Critical Care* **24**, 551–555 (2009).
30. Gupta, S., Singh, D., Sood, D. & Kathuria, S. Role of dexmedetomidine in early extubation of the intensive care unit patients. *J Anaesthesiol Clin Pharmacol* **31**, 92–98 (2015).
31. Hall, R. I. *et al.* Propofol vs midazolam for ICU sedation: a Canadian multicenter randomized trial. *Chest* **119**, 1151–1159 (2001).
32. Hellström, J., Öwall, A. & Sackey, P. V. Wake-up times following sedation with sevoflurane versus propofol after cardiac surgery. *Scand. Cardiovasc. J.* **46**, 262–268 (2012).
33. Herr, D. L., Sum-Ping, S. T. J. & England, M. ICU sedation after coronary artery bypass graft surgery: dexmedetomidine-based versus propofol-based sedation regimens. *J Cardiothorac. Vasc. Anesth.* **17**, 576–584 (2003).
34. Higgins, T. L. *et al.* Propofol versus midazolam for intensive care unit sedation after coronary artery bypass grafting. *Critical Care Medicine* **22**, 1415–1423 (1994).
35. Hu, Z. The use of dexmedetomidine combined with propofol in mechanically ventilated patients. *Medical Journal of Chinese People's Liberation Army* **40**, 479–483 (2015).
36. Huang, Z., Chen, Y.-S., Yang, Z.-L. & Liu, J.-Y. Dexmedetomidine Versus Midazolam for the Sedation of Patients with Non-invasive Ventilation Failure. *Intern. Med.* **51**, 2299–2305 (2012).
37. Huang, F. Sedative effects of dexmedetomidine in post-operative elder patients on mechanical ventilation. *Zhonghua yi xue za zhi* **94**, 3211–3215 (2014).
38. Jakob, S. M. *et al.* Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. *JAMA* **307**, 1151–1160 (2012).
39. Jalonen, J. *et al.* Dexmedetomidine as an anesthetic adjunct in coronary artery bypass grafting. *Anesthesiology* **86**, 331–345 (1997).
40. Kim, H.-J. *et al.* A comparison among infusion of lidocaine and dexmedetomidine alone and in combination in subjects undergoing coronary artery bypass graft: a randomized trial. *Contemp Clin Trials* **39**, 303–309 (2014).
41. MacLaren, R. *et al.* A Randomized, Double-Blind Pilot Study of Dexmedetomidine Versus Midazolam for Intensive Care Unit Sedation: Patient Recall of Their Experiences and Short-Term Psychological Outcomes. *Journal of Intensive Care Medicine* **30**, 167–175 (2015).
42. Maldonado, J. R. *et al.* Dexmedetomidine and the reduction of postoperative delirium after cardiac surgery. *Psychosomatics* **50**, 206–217 (2009).
43. Memiş, D., Kargi, M. & Sut, N. Effects of propofol and dexmedetomidine on indocyanine green elimination assessed with LİMON to patients with early septic shock: A pilot study. *Journal of Critical Care* **24**, 603–608 (2009).
44. Pandharipande, P. P. *et al.* Effect of Sedation With Dexmedetomidine vs Lorazepam on Acute Brain Dysfunction in Mechanically Ventilated Patients. *JAMA* **298**, 2644–2653 (2007).
45. Reade, M. C. *et al.* Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial. *Crit Care* **13**, R75 (2009).
46. Reade, M. C. *et al.* Effect of Dexmedetomidine Added to Standard Care on Ventilator-Free Time in Patients With Agitated Delirium: A Randomized Clinical Trial. *JAMA* **315**, 1460–1468 (2016).
47. Ren, J. *et al.* Protective effect of dexmedetomidine in coronary artery bypass grafting surgery. *Exp Ther Med* **6**, 497–502 (2013).
48. Riker, R. R. Dexmedetomidine vs Midazolam for Sedation of Critically Ill Patients <subtitle> A Randomized Trial </subtitle>. *JAMA* **301**, 489–499 (2009).
49. Roekaerts, P. M., Huygen, F. J. & de Lange, S. Infusion of propofol versus midazolam for sedation in the intensive care unit following coronary artery surgery. *J Cardiothorac. Vasc. Anesth.* **7**, 142–147 (1993).
50. Rubino, A. S. *et al.* Impact of clonidine administration on delirium and related respiratory weaning after surgical correction of acute type-A aortic dissection: results of a pilot study. *Interactive Cardiovascular and Thoracic Surgery* **10**, 58–62 (2010).
51. Sakarya, M. Propofol or midazolam infusion for sedation following myocardial revascularization | Miyokard revaskularizasyonu sonrası propofol ve midazolam ile sedasyon. *Türk Anesteziyoloji ve Reanimasyon* **27**, 171–176 (1999).
52. Shah, P. *et al.* Comparison of post-operative ICU sedation between dexmedetomidine and propofol in Indian population. *Indian J Crit Care Med* **18**, 291 (2014).
53. Shehabi, Y. *et al.* Early Goal-Directed Sedation Versus Standard Sedation in Mechanically Ventilated Critically Ill Patients. *Critical Care Medicine* **41**, 1983–1991 (2013).



54. Shehabi, Y. *et al.* Prevalence of delirium with dexmedetomidine compared with morphine based therapy after cardiac surgery: a randomized controlled trial (DEXmedetomidine COMpared to Morphine-DEXCOM Study). *Anesthesiology* **111**, 1075–1084 (2009).
55. Song, R. A study of using dexmedetomidine in ventilator bundle treatment in an ICU. *Chinese Critical Care Medicine* **27**, 836–840 (2015).
56. Soro, M. *et al.* Cardioprotective effect of sevoflurane and propofol during anaesthesia and the postoperative period in coronary bypass graft surgery: a double-blind randomised study. *Eur J Anaesthesiol* **29**, 561–569 (2012).
57. Srivastava, U. *et al.* Comparison of clonidine and dexmedetomidine for short-term sedation of intensive care unit patients. *Indian J Crit Care Med* **18**, 431–436 (2014).
58. Tasdogan, M., Memiş, D., Sut, N. & Yuksel, M. Results of a pilot study on the effects of propofol and dexmedetomidine on inflammatory responses and intraabdominal pressure in severe sepsis. *Journal of Clinical Anesthesia* **21**, 394–400 (2009).
59. Venn, R. M. & Grounds, R. M. Comparison between dexmedetomidine and propofol for sedation in the intensive care unit: patient and clinician perceptions. *Br J Anaesth* **87**, 684–690 (2001).
60. Wan, L. Comparison of sedative effect of dexmedetomidine and midazolam for post-operative patients undergoing mechanical ventilation in surgical intensive care unit. *Chinese Critical Care Medicine* **23**, 543–546 (2011).
61. Weinbroum, A. A. *et al.* Midazolam versus propofol for long-term sedation in the ICU: a randomized prospective comparison. *Intensive Care Medicine* **23**, 1258–1263 (1997).
62. Yapici, N. *et al.* Dexmedetomidine in cardiac surgery patients who fail extubation and present with a delirium state. *The Heart Surgery Forum* **14**, E93–8 (2011).
63. Zhang, C. Clinical study of different types of sedation and analgesia in patients with mechanical ventilation in icu. *Medical Journal of Wuhan University* **37**, 322–326 (2016).
64. Ruokonen, E. *et al.* Dexmedetomidine versus propofol/midazolam for long-term sedation during mechanical ventilation. *Intensive Care Medicine* **35**, 282–290 (2009).
65. Fraser, G. L. *et al.* Benzodiazepine versus nonbenzodiazepine-based sedation for mechanically ventilated, critically ill adults: a systematic review and meta-analysis of randomized trials. *Critical Care Medicine* **41**, S30–8 (2013).
66. Chen, K. *et al.* Alpha-2 agonists for long-term sedation during mechanical ventilation in critically ill patients. *Cochrane Database Syst Rev* **1**, CD010269 (2015).
67. Cruickshank, M. *et al.* Alpha-2 agonists for sedation of mechanically ventilated adults in intensive care units: a systematic review. *Health Technology Assessment* **20**, 1–118 (2016).
68. Zhang, Z., Xu, X. & Ni, H. Small studies may overestimate the effect sizes in critical care meta-analyses: a meta-epidemiological study. *Crit Care* **17**, R2 (2013).

### Author Contributions

Z.Z. conceived the idea and drafted the manuscript; K.C. and H.N. searched the electronic databases and helped statistical analysis; X.Z., and H.F. designed the forms for data extraction and extracted relevant data.

### Additional Information

**Supplementary information** accompanies this paper at <http://www.nature.com/srep>

**Competing Interests:** The authors declare no competing financial interests.

**How to cite this article:** Zhang, Z. *et al.* Sedation of mechanically ventilated adults in intensive care unit: a network meta-analysis. *Sci. Rep.* **7**, 44979; doi: 10.1038/srep44979 (2017).

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2017